• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Is Tilray's $2B Valuation Just The Beginning? Analyst Sees $10B Market Opportunity, Initiates Coverage

    6/28/24 9:50:01 AM ET
    $BUD
    $TLRY
    Beverages (Production/Distribution)
    Consumer Staples
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $BUD alert in real time by email

    With a $2 billion valuation, Tilray Brands (NASDAQ:TLRY) ranks as the largest cannabis company outside the U.S., leading in international sales and the Canadian recreational market. Pablo Zuanic of Zuanic & Associates has initiated coverage on Tilray with a 'Neutral' rating, highlighting the company's significant potential in global markets.

    “In a bull-case scenario, the stock could be near $7 a year from now. On near-term execution and reinvestment risk, we prefer to start at Neutral but are long-term constructive,” Zuanic wrote. “Tilray is focused on building an alcohol drinks ecosystem in the US that it believes could yield revenue synergies in the future with cannabis.”

    Zuanic’s analysis projects a strategic premium on Tilray’s diversified cannabis operations.

    His financial projections suggest that Tilray’s sales will rise from $784 million in FY24 to $924 million in FY26, with an improvement in earnings per share from -$0.32 in FY24 to -$0.10 in FY26.

    Strategic Assets And U.S. Opportunities

    Tilray's diversified portfolio includes beverages, wellness products and distribution, which might benefit from U.S. federal legalization.

    Despite challenges in acquiring U.S. assets due to federal restrictions, upcoming regulatory changes could provide a strategic window for Tilray.

    The company recently announced a $250 million equity offering which might support its U.S. strategy. Tilray has invested in the U.S. market through debt holdings in MedMen, expecting to equitize this investment upon federal permissibility.

    International Growth And Valuation

    The international medical cannabis market, with a potential $10 billion addressable market, remains a significant growth area. Tilray, with established operations in countries like Portugal, is well-positioned to capitalize on these opportunities. The company's strategic focus could increase its market valuation by several folds, contingent on its ability to maintain a competitive edge and execute its strategy effectively.

    Canadian Market Dynamics

    In Canada, Tilray maintains its dominance in the recreational market but faces challenges like market saturation and regulatory hurdles. The Canadian market has shown slower growth compared to U.S. states, with stringent marketing regulations and a high excise tax burden impacting profitability.

    Stock Performance And Investment Outlook

    The analysis shows mixed performance with potential for both upside in international expansion and risks from slow growth or regulatory challenges. Tilray's stock has shown resilience with a modest year-over-year increase, amidst broader market fluctuations. While the current stance is neutral, Tilray's strategic investments in the U.S. market, its diversified portfolio and its strong position in international markets and the Canadian recreational market bolster Zuanic's positive outlook.

    “Tilray's U.S. F&B footprint could prove to be synergistic upon federal legalization of cannabis. The stock's peer valuation premium ($2Bn EV), liquidity, significant cash balance, and NASDAQ listing are all key strategic assets,“ said Zuanic.

    These investing issues will be a hot topic at the upcoming Benzinga Cannabis Capital Conference in Chicago this Oct. 8-9. Join us to get more insight into what the wave of weed legalization means for the future of investing in the industry. Hear directly from top executives, investors, advocates, and policymakers. Get your tickets now before prices go up by following this link.

    The US Alcohol Business And Non-Alcoholic Drinks

    Starting with the Sweetwater (craft beer) deal in November 2020, Tilray entered the alcohol beverage space, both as a diversification move and to add future optionality in the event alcohol brands and distribution overlap with recreational cannabis when federally permissible.

    Zuanic explains that given the blurring lines between hemp derivatives and THC cannabis, part of these revenue synergies may be garnered before actual legalization in the form of hemp-based drinks.

    “With annualized proforma revenues approaching $300 million, factoring in the recent acquisition of eight craft brands from Anheuser-Busch (NYSE:BUD), Tilray aims to become a top 12 beverage alcohol company in the US market and is already the 5th largest craft brewer,” Zuanic wrote. “Importantly, this expansion has bolstered the company’s EBITDA and cash flow base, with management seeing top-line growth potential through innovation, investment, and expanded distribution of these brands.”

    Photo: AI-Generated Image. 

    Get the next $BUD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BUD
    $TLRY

    CompanyDatePrice TargetRatingAnalyst
    Tilray Brands Inc.
    $TLRY
    1/27/2026Hold
    Canaccord Genuity
    Anheuser-Busch Inbev SA Sponsored ADR (Belgium)
    $BUD
    11/28/2025Buy → Hold
    Deutsche Bank
    Anheuser-Busch Inbev SA Sponsored ADR (Belgium)
    $BUD
    11/19/2025$75.00Overweight
    Wells Fargo
    Anheuser-Busch Inbev SA Sponsored ADR (Belgium)
    $BUD
    5/12/2025$88.00Neutral → Buy
    Goldman
    Anheuser-Busch Inbev SA Sponsored ADR (Belgium)
    $BUD
    4/2/2025Buy
    Berenberg
    Anheuser-Busch Inbev SA Sponsored ADR (Belgium)
    $BUD
    3/27/2025$70.00Hold → Buy
    Argus
    Anheuser-Busch Inbev SA Sponsored ADR (Belgium)
    $BUD
    3/3/2025Hold → Buy
    Deutsche Bank
    Anheuser-Busch Inbev SA Sponsored ADR (Belgium)
    $BUD
    10/8/2024$88.00Buy → Hold
    TD Cowen
    More analyst ratings

    $BUD
    $TLRY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cohen Steven Michael exercised 12,438 shares at a strike of $8.99 (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    1/8/26 4:24:12 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    President and CEO Simon Irwin D exercised 706,216 shares at a strike of $0.58 and covered exercise/tax liability with 374,295 shares, increasing direct ownership by 7% to 4,826,493 units (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    8/4/25 4:07:08 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Financial Officer Merton Carl A exercised 93,928 shares at a strike of $0.58 and covered exercise/tax liability with 49,782 shares, increasing direct ownership by 5% to 920,497 units (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    8/4/25 4:06:42 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $BUD
    $TLRY
    SEC Filings

    View All

    SEC Form 144 filed by Anheuser-Busch Inbev SA Sponsored ADR (Belgium)

    144 - Anheuser-Busch InBev SA/NV (0001668717) (Subject)

    2/13/26 4:24:51 PM ET
    $BUD
    Beverages (Production/Distribution)
    Consumer Staples

    SEC Form 6-K filed by Anheuser-Busch Inbev SA Sponsored ADR (Belgium)

    6-K - Anheuser-Busch InBev SA/NV (0001668717) (Filer)

    2/13/26 7:28:49 AM ET
    $BUD
    Beverages (Production/Distribution)
    Consumer Staples

    SEC Form 6-K filed by Anheuser-Busch Inbev SA Sponsored ADR (Belgium)

    6-K - Anheuser-Busch InBev SA/NV (0001668717) (Filer)

    1/30/26 4:02:46 PM ET
    $BUD
    Beverages (Production/Distribution)
    Consumer Staples

    $BUD
    $TLRY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Global General Counsel Gendel Mitchell exercised 93,928 shares at a strike of $0.58, covered exercise/tax liability with 49,782 shares and bought $3,496 worth of shares (6,000 units at $0.58), increasing direct ownership by 8% to 698,287 units (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    8/4/25 4:06:19 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    President and CEO Simon Irwin D bought $100,106 worth of shares (165,000 units at $0.61), increasing direct ownership by 4% to 3,941,633 units (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    7/30/25 6:52:32 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Financial Officer Merton Carl A bought $19,939 worth of shares (33,500 units at $0.60), increasing direct ownership by 4% to 798,069 units (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    7/30/25 3:12:46 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $BUD
    $TLRY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tilray Expands UK Pharmaceutical Access Through Strategic Agreement with Smartway Pharmaceuticals

    NEW YORK and LONDON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Tilray Pharma the pharmaceutical division of Tilray Brands, Inc. (NASDAQ:TLRY, TSX:TLRY), today announced that its European pharmaceutical distribution business, CC Pharma, has entered into a strategic agreement with Smartway Pharmaceuticals, a leading UK-based pharmaceutical distribution partner, to expand the availability of pharmaceutical products across the United Kingdom. Through this agreement, CC Pharma and Smartway will jointly support the expansion of parallel import and specialist pharmaceutical supply in the UK, leveraging Smartway's established national distribution infrastructure to facilitate the delivery of pharmaceutic

    2/12/26 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    AB InBev Reports Full Year and Fourth Quarter 2025 Results

    Underlying EPS increased by 6% with continued margin expansion and free cash flow generation of 11.3 billion USD Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260211688662/en/Figure 14. Terms and debt repayment schedule as of 31 December 2025 (billion USD) Regulated and inside information1 "Beer plays an important role in bringing people together and creating moments of celebration. In 2025, we executed our strategy, made disciplined capital allocation choices and delivered growth within our outlook for the year, even as we navigated a dynamic consumer envir

    2/12/26 1:01:00 AM ET
    $APO
    $BUD
    Investment Managers
    Finance
    Beverages (Production/Distribution)
    Consumer Staples

    Breckenridge Distillery Appoints Romano Beverage for Distribution in Illinois

    BRECKENRIDGE, Colo., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Breckenridge Distillery, an award-winning craft distillery and spirits brand owned by Tilray Brands, Inc. (NASDAQ:TLRY, TSX:TLRY), has announced appointment of Romano Beverage, a respected partner, to manage distribution responsibilities within the state. Romano Beverage, a trusted leader in beverage distribution, is now overseeing Breckenridge Distillery's full spirits collection across Illinois—including its celebrated bourbon whiskey, whiskey, rum, vodka, gin, and newly launched Mountain Shot. Romano's strong presence in Illinois and dedication to exceptional service make them the perfect partner to help Breckenridge Distillery thr

    2/4/26 8:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $BUD
    $TLRY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Tilray

    Canaccord Genuity initiated coverage of Tilray with a rating of Hold

    1/27/26 9:29:20 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Anheuser-Busch InBev downgraded by Deutsche Bank

    Deutsche Bank downgraded Anheuser-Busch InBev from Buy to Hold

    11/28/25 7:17:58 AM ET
    $BUD
    Beverages (Production/Distribution)
    Consumer Staples

    Wells Fargo initiated coverage on Anheuser-Busch InBev with a new price target

    Wells Fargo initiated coverage of Anheuser-Busch InBev with a rating of Overweight and set a new price target of $75.00

    11/19/25 8:56:04 AM ET
    $BUD
    Beverages (Production/Distribution)
    Consumer Staples

    $BUD
    $TLRY
    Leadership Updates

    Live Leadership Updates

    View All

    Breckenridge Distillery Appoints Romano Beverage for Distribution in Illinois

    BRECKENRIDGE, Colo., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Breckenridge Distillery, an award-winning craft distillery and spirits brand owned by Tilray Brands, Inc. (NASDAQ:TLRY, TSX:TLRY), has announced appointment of Romano Beverage, a respected partner, to manage distribution responsibilities within the state. Romano Beverage, a trusted leader in beverage distribution, is now overseeing Breckenridge Distillery's full spirits collection across Illinois—including its celebrated bourbon whiskey, whiskey, rum, vodka, gin, and newly launched Mountain Shot. Romano's strong presence in Illinois and dedication to exceptional service make them the perfect partner to help Breckenridge Distillery thr

    2/4/26 8:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    AB InBev and International Cricket Council Announce Landmark Global Partnership

    World's Leading Brewer becomes the Official Beer Partner of the ICC The International Cricket Council (ICC) announced AB InBev (Euronext: ABI) (NYSE:BUD) (MEXBOL: ANB) (JSE: ANH), the world's leading brewer, will become the Official Beer Partner for all major ICC tournaments starting in 2026. The partnership will be led by Budweiser 0.0, Budweiser's no-alcohol beer in India, with other ABI mega brands activating in Europe and Africa. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251211250826/en/AB InBev and ICC announce global partnership From attending a match live in-stadium to watching one at a bar or pub with friends, with

    12/11/25 4:31:00 AM ET
    $BUD
    Beverages (Production/Distribution)
    Consumer Staples

    Corona Cero Brings Golden Moments to the Mountains of Milano Cortina 2026

    First-ever no-alcohol beer sponsor of Olympic Winter Games celebrates "For Every Golden Moment" platform with consumers globally As the 100-day countdown to the Olympic Winter Games continues, and in a year the global Corona brand is celebrating its 100th anniversary, Corona Cero is officially set to bring golden moments to the slopes of Milano Cortina 2026. As the first no-alcohol beer sponsor of the Winter Olympics, the brand is revving up its "For Every Golden Moment" global platform to invite consumers to celebrate every golden moment any time, any season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105994873/en/Corona

    11/5/25 4:30:00 AM ET
    $BUD
    Beverages (Production/Distribution)
    Consumer Staples

    $BUD
    $TLRY
    Financials

    Live finance-specific insights

    View All

    AB InBev Reports Full Year and Fourth Quarter 2025 Results

    Underlying EPS increased by 6% with continued margin expansion and free cash flow generation of 11.3 billion USD Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260211688662/en/Figure 14. Terms and debt repayment schedule as of 31 December 2025 (billion USD) Regulated and inside information1 "Beer plays an important role in bringing people together and creating moments of celebration. In 2025, we executed our strategy, made disciplined capital allocation choices and delivered growth within our outlook for the year, even as we navigated a dynamic consumer envir

    2/12/26 1:01:00 AM ET
    $APO
    $BUD
    Investment Managers
    Finance
    Beverages (Production/Distribution)
    Consumer Staples

    Tilray Brands to Announce Second Quarter Fiscal Year 2026 Financial Results on January 8, 2026

    NEW YORK and LEAMINGTON, Ontario, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a global lifestyle and consumer packaged goods company at the forefront of the cannabis, beverage and wellness industries, today announced that the Company will release its financial results for the second fiscal quarter which ended November 30, 2025, after the financial markets close on Thursday, January 8, 2026. Live Conference Call and Audio Webcast Tilray will host a live conference call, which will be webcast, to discuss these results at 4:30 PM Eastern Time on the same day. The webcast can be accessed on the Events & Presentations section of T

    12/22/25 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    AB InBev Reports Third Quarter 2025 Results

    Consistent execution of our strategy delivered an EBITDA increase of 3.3% with margin expansion and low-single digit Underlying EPS growth Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029571716/en/ Regulated and inside information1 "Driven by the momentum of our megabrands and our innovation in balanced choices and Beyond Beer, our business delivered continued top- and bottom-line growth, even as we navigated a dynamic consumer environment. Given the progress we have made on our deleveraging and solid year-to-date financial results we have announced a ne

    10/30/25 2:05:00 AM ET
    $BUD
    Beverages (Production/Distribution)
    Consumer Staples

    $BUD
    $TLRY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Anheuser-Busch Inbev SA Sponsored ADR (Belgium)

    SC 13D/A - Anheuser-Busch InBev SA/NV (0001668717) (Subject)

    10/1/24 5:20:48 PM ET
    $BUD
    Beverages (Production/Distribution)
    Consumer Staples

    Amendment: SEC Form SC 13D/A filed by Anheuser-Busch Inbev SA Sponsored ADR (Belgium)

    SC 13D/A - Anheuser-Busch InBev SA/NV (0001668717) (Subject)

    10/1/24 4:59:00 PM ET
    $BUD
    Beverages (Production/Distribution)
    Consumer Staples

    Amendment: SEC Form SC 13D/A filed by Anheuser-Busch Inbev SA Sponsored ADR (Belgium)

    SC 13D/A - Anheuser-Busch InBev SA/NV (0001668717) (Subject)

    6/21/24 4:30:51 PM ET
    $BUD
    Beverages (Production/Distribution)
    Consumer Staples